Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate anti-malarial/anti-infective single-agent and in combination for
patients with confirmed COVID-19 infection. The first combination to be evaluated is
atovaquone and azithromycin.